NASDAQ:CDLX - Cardlytics Stock Price, Price Target & More

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Cardlytics (NASDAQ:CDLX) posted its quarterly earnings results on Monday, March, 19th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.25. The business earned $39.27 million during the quarter, compared to analysts' expectations of $38.48 million. View Cardlytics' Earnings History.

6 equities research analysts have issued 1 year price objectives for Cardlytics' shares. Their predictions range from $19.00 to $25.00. On average, they anticipate Cardlytics' share price to reach $22.40 in the next year. View Analyst Ratings for Cardlytics.

Cardlytics saw a increase in short interest in April. As of April 30th, there was short interest totalling 861,027 shares, an increase of 40.0% from the April 13th total of 614,820 shares. Based on an average daily trading volume, of 94,969 shares, the short-interest ratio is currently 9.1 days. Approximately 10.2% of the shares of the company are sold short.

Some companies that are related to Cardlytics include Jianpu Technology (JT), Internet Initiative Japan (IIJI), TrueCar (TRUE), HealthStream (HSTM), 21Vianet Group (VNET), Model N (MODN), Internap (INAP), Rubicon Project (RUBI), Edgewater Technology (EDGW), Sify (SIFY), Synacor (SYNC), AutoWeb (AUTO), ChinaNet Online (CNET), MassRoots (MSRT) and GigaMedia (GIGM).

(CDLX) raised $76 million in an initial public offering on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics' quiet period expired on Wednesday, March 21st. Cardlytics had issued 5,400,000 shares in its public offering on February 9th. The total size of the offering was $70,200,000 based on an initial share price of $13.00. During the company's quiet period, insiders and underwriters involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Media headlines about CDLX stock have trended positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cardlytics earned a news impact score of 0.45 on Accern's scale. They also assigned media stories about the company an impact score of 44.88 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Cardlytics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Polaris Venture Management Co. V L.L.C. (13.18%), Federated Investors Inc. PA (2.00%), BlackRock Inc. (1.17%), Millennium Management LLC (0.87%), Citadel Advisors LLC (0.53%) and Kornitzer Capital Management Inc. KS (0.31%). Company insiders that own Cardlytics stock include David Thomas Evans and Scott D Grimes. View Institutional Ownership Trends for Cardlytics.

CDLX stock was bought by a variety of institutional investors in the last quarter, including Polaris Venture Management Co. V L.L.C., Federated Investors Inc. PA, BlackRock Inc., Millennium Management LLC, Citadel Advisors LLC, Kornitzer Capital Management Inc. KS, Northern Trust Corp and Penn Capital Management Co. Inc.. Company insiders that have bought Cardlytics stock in the last two years include David Thomas Evans and Scott D Grimes. View Insider Buying and Selling for Cardlytics.

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CDLX stock can currently be purchased for approximately $19.43.

Cardlytics has a market capitalization of $393.73 million and generates $130.37 million in revenue each year. The company earns $-19,640,000.00 in net income (profit) each year or ($8.02) on an earnings per share basis. Cardlytics employs 342 workers across the globe.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]